Israel
· Delayed Price · Currency is ILS · Price in ILANRGene Technologies Statistics
Total Valuation
NRGene Technologies has a market cap or net worth of ILS 45.74 million. The enterprise value is 39.71 million.
| Market Cap | 45.74M |
| Enterprise Value | 39.71M |
Important Dates
The next estimated earnings date is Thursday, November 21, 2024.
| Earnings Date | Nov 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NRGene Technologies has 12.89 million shares outstanding. The number of shares has increased by 0.36% in one year.
| Shares Outstanding | 12.89M |
| Shares Change (YoY) | +0.36% |
| Shares Change (QoQ) | +0.05% |
| Owned by Insiders (%) | 35.70% |
| Owned by Institutions (%) | 7.00% |
| Float | 6.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.61 |
| PB Ratio | 2.22 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.31 |
| EV / Sales | 6.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.48 |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 25.11.
| Current Ratio | 1.69 |
| Quick Ratio | 1.60 |
| Debt / Equity | 25.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.32 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -60.53% and return on invested capital (ROIC) is -28.67%.
| Return on Equity (ROE) | -60.53% |
| Return on Assets (ROA) | -22.61% |
| Return on Capital (ROIC) | -28.67% |
| Revenue Per Employee | 117,170 |
| Profits Per Employee | -344,507 |
| Employee Count | 50 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.34% in the last 52 weeks. The beta is -0.32, so NRGene Technologies's price volatility has been lower than the market average.
| Beta (5Y) | -0.32 |
| 52-Week Price Change | +23.34% |
| 50-Day Moving Average | 366.64 |
| 200-Day Moving Average | 344.21 |
| Relative Strength Index (RSI) | 54.97 |
| Average Volume (20 Days) | 5,235 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NRGene Technologies had revenue of ILS 5.86 million and -17.23 million in losses. Loss per share was -1.40.
| Revenue | 5.86M |
| Gross Profit | 2.64M |
| Operating Income | -15.07M |
| Pretax Income | -17.26M |
| Net Income | -17.23M |
| EBITDA | -14.16M |
| EBIT | -15.07M |
| Loss Per Share | -1.40 |
Balance Sheet
The company has 11.33 million in cash and 5.09 million in debt, giving a net cash position of 6.24 million or 0.48 per share.
| Cash & Cash Equivalents | 11.33M |
| Total Debt | 5.09M |
| Net Cash | 6.24M |
| Net Cash Per Share | 0.48 |
| Equity (Book Value) | 20.27M |
| Book Value Per Share | 1.60 |
| Working Capital | 6.31M |
Cash Flow
In the last 12 months, operating cash flow was -15.38 million and capital expenditures -625,007, giving a free cash flow of -16.01 million.
| Operating Cash Flow | -15.38M |
| Capital Expenditures | -625,007 |
| Free Cash Flow | -16.01M |
| FCF Per Share | -1.24 |
Margins
Gross margin is 45.12%, with operating and profit margins of -257.26% and -294.02%.
| Gross Margin | 45.12% |
| Operating Margin | -257.26% |
| Pretax Margin | -294.60% |
| Profit Margin | -294.02% |
| EBITDA Margin | -241.77% |
| EBIT Margin | -257.26% |
| FCF Margin | -273.20% |
Dividends & Yields
NRGene Technologies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.36% |
| Shareholder Yield | -0.36% |
| Earnings Yield | -39.41% |
| FCF Yield | -34.99% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |